Lawmakers continued to negotiate the terms of opioid legislation, with the Senate standing firm in its position that insurance companies should not put obstacles in the way of medication-assisted therapy.

The Senate took up a House opioids bill (HB 21) but tagged on an amendment that includes appropriating $54.5 million for such things as outpatient and residential treatment. It also would ban insurers and HMOs from using prior authorization or “step therapy” or making other requirements as a prerequisite to the use of medication-assisted therapy in treating substance abuse.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]